JWH-211

JWH-211 is a synthetic cannabinoid that acts as a potent agonist at both the CB1 and CB2 cannabinoid receptors. It is part of the naphthoylindole family of synthetic cannabinoids, which were originally developed for research purposes to study the endocannabinoid system.

Chemical Structure and Properties

JWH-211 is chemically classified as a naphthoylindole, with the systematic IUPAC name of (1-(5-fluoropentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone. The compound features a fluoropentyl chain attached to the indole core, which is linked to a naphthyl group via a ketone bridge. This structure is similar to other synthetic cannabinoids, such as JWH-018 and JWH-073, but with specific modifications that affect its binding affinity and selectivity for cannabinoid receptors.

Pharmacology

JWH-211 is known for its high affinity for both CB1 and CB2 receptors, with a slight preference for CB2. This makes it a useful compound for studying the differential effects of cannabinoid receptor activation. The activation of CB1 receptors is primarily associated with psychoactive effects, while CB2 receptor activation is linked to anti-inflammatory and immunomodulatory effects.

Receptor Binding

- CB1 Receptor: JWH-211 binds to the CB1 receptor with a high affinity, contributing to its psychoactive properties. - CB2 Receptor: It has an even higher affinity for the CB2 receptor, which is predominantly expressed in the immune system and peripheral tissues.

Legal Status

The legal status of JWH-211 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. It is often included in legislation targeting synthetic cannabinoids and "designer drugs."

Research and Applications

JWH-211 has been used in scientific research to explore the roles of CB1 and CB2 receptors in various physiological and pathological processes. Its ability to selectively activate these receptors makes it a valuable tool in cannabinoid research, particularly in studies investigating the therapeutic potential of CB2 receptor agonists in conditions such as chronic pain, inflammation, and autoimmune diseases.

Safety and Toxicology

As with many synthetic cannabinoids, the safety profile of JWH-211 is not well-established. It is known that synthetic cannabinoids can produce a range of adverse effects, including anxiety, paranoia, tachycardia, and in severe cases, psychosis. The lack of comprehensive toxicological data makes it difficult to assess the full risk profile of JWH-211.

Also see

• Synthetic cannabinoids
• Endocannabinoid system
• CB1 receptor
• CB2 receptor
• JWH-018
• JWH-073